08:12 AM EDT, 10/07/2024 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Monday it has launched a global phase 3 trial to assess the efficacy and safety of NTLA-2002 in 60 adults with Type 1 or Type 2 hereditary angioedema.

The trial's primary endpoint is the change in number of hereditary angioedema attacks from the fifth week to the 28th week of patients receiving the single-dose treatment meant to prevent potentially life-threatening swelling attacks in HAE patients, the company said.

The phase 3 trial launch is based on positive safety and efficacy data from the ongoing phase 1/2 study, said Intellia Therapeutics ( NTLA ), which cited "dramatic reductions in attack rate" and "consistent, deep and durable reductions in kallikrein levels" from the interim phase 1 clinical data.

Price: 17.92, Change: -0.07, Percent Change: -0.39